Overproduction of the bleomycin-binding proteins from bleomycin-producing Streptomyces verticillus and a methicillin-resistant Staphylococcus aureus in Escherichia coli and their immunological characterisation  by Sugiyama, Masanori et al.
FEBS Letters 362 (1995) 80 84 FEBS 15290 
Overproduction of the bleomycin-binding proteins from 
bleomycin-producing Streptomyces verticillus and a methicillin-resistant 
Staphylococcus aureus in Escherichia coli and their immunological 
characterisation 
Masanori Sugiyama '*, Takanori Kumagai a, Hiroaki Matsuo a, Md. Zahurul Alam Bhuiyan b, 
Kazuhiro Ueda b, Hiroshi Mochizuki c, Norio Nakamura  c, Julian E. Davies d 
"Institute of Pharmaceutical Sciences and bDepartment of Paediatrics, Hiroshima University School of Medicine, Kasumi 1-2-3, 
Minami-ku, Hiroshima 734, Japan 
CBiosciences Research Laboratory, Mochida Pharmaceutieal Co. Ltd., 1-1-1, Kamiya, Kita-ku, Tokyo 115, Japan 
JDepartment of Microbiology, The University of British Columbia, 300-6174 University Boulevard, Vancouver, BC V6T 1Z3, Canada 
Received 31 January 1995 
Abstract The bleomycin-binding proteins designated BLMA 
and BLMS, which confer resistance to bleomycin (Bm), from 
Bin-producing Streptomyces verticillus ATCC15003 and a meth- 
icillin-resistant Staphylococcus aureus B-26, respectively, were 
overexpressed in Escherichia coli. The present study showed that 
both BLMA and BLMS quench the antibacterial activity of Bm 
by the binding to the drug. To immuno-chracterize the Bm-bind- 
ing proteins, we constructed a monoclonai antibody against 
BLMA. The antibody, designated 893-12, did not cross react to 
BLMS and another Bin-binding protein from tallysomycin-pro- 
ducing Streptoalloteichus hindustanus. Although the ability of Bm 
to cleavage DNA was eliminated by a binding of BLMA to Bm, 
as shown by Sugiyama et al. [Gene 151 (1994) 11-15], the Bm- 
induced DNA degradation was restored by pre-incubation of 
BLMA with the anti-BLMA monoclonai antibody. 
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1. Introduction 
Bleomycin (Bm) and the related antibiotic, phleomycin and 
tallysomycin i hibit DNA synthesis in bacterial and mammal- 
ian cells [1]. The antibiotic-producing microorganisms ust be 
protected from the lethal effect of their own product. We have 
cloned and sequenced two independent genes, designated blmA 
and blmB, encoding Bm resistance determinants from Bm-pro- 
ducing Streptomyces verticillus ATCC15003 [2]. The genes 
blmA and blmB were shown to encode a Bin-binding protein 
and a Bm N-acetyltransferase [2-3], respectively. A gene desig- 
nated Shble, which confers resistance to Bm, phleomycin and 
tallysomycin, has been cloned from tallysomycin-producing 
Streptoalloteichus hindustanus belong to a family Actinopla- 
naceae and sequenced [4]. The Shble gene encoded a small 
acidic protein (Mr = 13,665) which was a binding protein with 
a strong affinity for Bm [5]. 
Almost all strains of methicillin-resistant Staphylococcus au- 
reus (MRSA), isolated in Hiroshima University Hospital from 
October 1990 to April 1992, were resistant to Bm, although the 
drug has been not used as an antibacterial gent. We have 
cloned and sequenced a gene encoding a Bm resistance determi- 
nant from the chromosomal DNA of MRSA B-26 isolated 
clinically in the hospital [6]. The sequence analysis revealed that 
the gene, designated as blmS in the present study, was identical 
to that located on the staphylococcal p asmid pUB110 [6,7]. 
Interestingly, an inverted repeat, designated IR-r in an insertion 
sequence IS431mec which possibly mediated the transposition 
of blmS into the chromosome from pUB110, was located up- 
stream from blmS of MRSA B-26 [6]. A transposon Tn5 also 
carries a Bin-resistance determinant [8]. Although these Bm- 
resistance genes from MRSA B-26, pUB110 and Tn5 have been 
sequenced [6-9], the characterisation f the gene products and 
the biochemical mechanism of resistance has not yet been elu- 
cidated in detail. 
The aim of the present study is to overproduce and to char- 
acterize the blmA and blmS products, designated BLMA and 
BLMS, respectively, in Escherichia coli host. These are the first 
purification of the bleomycin-binding proteins. Moreover, this 
paper report on the successful generation of the anti-BLMA 
monoclonal antibody for the immunological characterisation 
of BLMA and BLMS, 
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Abbreviations." Ap, ampicillin; Bm, bleomycin; blmA, a gene encoding 
Bm-binding protein from Streptomyces verticillus; BLMA, a protein 
encoded by blmA; blmS, a gene encoding bleomycin-binding protein 
from a methicillin resistant Staphylococcus aureus; BLMS, a protein by 
blmS; IPTG, isopropyl-fl-o-thiogalactoside; malE, a gene encoding 
MBP; MBP, maltose-binding protein, MBP/BLMA, a fusion protein 
between MBP and BLMA; MRSA, methicillin resistant Staphylococcus 
aureus; PAGE, polyacrylamide g l electrophoresis; SDS, sodium do- 
decyl sulfate. 
2.1. Bacterial strains and plasmids 
E. coli TGI harboring the pUC18-based p 181EB 1 plasmid [2] carries 
bhnA cloned from the chromosomal DNA of Bm-producing S. verticil- 
lus ATCC15003. E. coli HB101 and pKKtrp plasmid were used to 
overexpress blmS from MRSA B-26. 
2.2. Construction of plasmids to overexpress BLMS and BLMA in 
E. coil 
To amplify the blmA structural gene (369 bp) having EeoRI and 
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BamHl sites at the 5'- and 3'- adjacent regions, respectively (Fig. 1), a 
sense- and an antisense-oligonucleotide PCR primers were designed 
and chemically syntheized, based on the nucleotide sequence of blmA 
[2]. The plasmid pl81EB1 was used as a template for amplification of 
blmA by PCR. The amplified DNA fragment was inserted into the 
EeoRI-and BamHI-digested pUC18 to generate pUAB10. The 
pUAB10 plasmid was digested with EcoRI and PstI and the small 
fragment was subcloned into pKK223-3 [10] (Pharmacia LKB Biotech- 
nology product) digested with the same restriction enzymes, to generate 
pUAB20. The EcoRI-PstI fragment from pUAB20 was inserted into 
the EcoRI-PstI digested pMALc-2 (New England Biolabs) to create 
pMALB10. E. coli host harboring pMALB10 was resistant even to 
1,000/tg Bm/ml. 
To overexpress BLMS under the control of trp prpmoter, the blmS 
structural gene having EcoRI and BamHI sites at the 5' and 3'-adjacent 
regions [2], respectively, was inserted into the same enzymes-digested 
pKKtrp plasmid to generate pKKtrpS and introduced in E. coli 
HB101. The transformed cells were also resistant o over 1,000 ¢tg 
Brn/ml. 
2.3. Isolation of BLMA and BLMS 
F~ coli TB 1 harboring pMALB I 0 was grown in LB medium contain- 
ing 200/tg Ap/ml. To induce the expression of fusion gene, IPTG was 
added at a final concentration of 1 mM. The cells were grown at 37°C 
until stationary phase and sonicated. The cell extract was subjected to 
the column (1.0 x 10 cm) of amylose resin according to the instruction 
manual of a Protein Fusion and Purification System Kit (New England 
Biolabs) based on the previous report [11]. The column was washed 
with buffer I (20 mM Tris-HCl (pH 7.4), 200 mM NaC1, 1 mM EDTA- 
Na 3 and 10 mM 2-mercaptoethanol). The elution was done with buffer 
I containing 10 mM maltose. After the fusion protein (MBP/BLMA) 
was digested with blood coagulation factor X, protease, the digests 
were subjected to a hydroxyapatite column chromatography to remove 
maltose and then applied to the amylose resin column. BLMA was 
purified to homogeneity away from MBP by the affinity chromatogra- 
phy step. 
E. coli HB101 harboring pKKtrpS was cultivated in M9-casamino 
acid medium [12] containing 100,ug Ap/ml. To induce expression of the 
trp promoter-controlled blmS gene, 3-indoleacrylic acid was added at 
a final concentration of 0.13 mM during the exponential phase of 
growth. The harvested cells were ground with quartz sands and centri- 
fuged at 18,000 × g for 20 min. Solid ammonium sulfate was added to 
the supernatant fluid at 20% saturation and the resulting precipitate 
was removed by centrifugation. BLMS was precipitated by addition of 
ammonium sulfate at 40% saturation, dissolved in the small amount of 
buffer III (5 mM Tris-HC1 (pH 7.2), 0.5 mM EDTA and 5% glycerol) 
and subjected to DEAE-Sepharose CL-6B column (1 cm × 20 cm) 
equilibrated with 10 mM Tris-HCl (pH 7.2) and eluted with the same 
buffer containing 0-1 M NaC1 (linear gradient of concentration). One 
of four fractions eluted with approximately 0.5 M NaCI contained 
BLMS together with the very insignificant impurities. 
2.4. N-termial amino acid sequence 
The N-terminal amino acid sequences of BLMA and BLMS were 
determined by Edman degradation method using the autosequencer. 
2.5. Generation oJanti-BLMA monoclonal ntibody 
The purifed MBP/BLMA (50/,tg) in saline (50 pl) was mixed with 
Freund's complete adjuvant (50 pl) and injected intraperitoneally to 
BALB/c mice. At 12, 18 and 31 days, respectively, they were boosted 
with 100 pg of the MBP/BLMA. The spleen cells from the immunized 
mouse, harvested at 3 days after the last injection, were fused with 
P3/X63-Ag-8.UI murine myeloma cells. Hybridomas-secreting anti- 
MBP/BLMA antibodies were screened by ELISA: that is, 96-wells 
immunoplates (MaxiSorp, Nunc, Roskilde, Denmark) were coated 
with MBP/BLMA, BLMA or MBP (1 pg/ml,  100 ml/well) in PBS (76 
mM phosphate, 0.45% NaC1, pH 6.4) at 37°C for 1 h, washed with the 
deionized water and then blocked with 0.5% bovine serum albumin in 
PBS at 25°C for 2 h. The antigen-coated wells were incubated with the 
culture supernatants from hybridomas for 1 h at room temperature, 
followed by the incubation with horseradish peroxidase(HRP)-labeled 
anti-mouse immunoglobulins (Dako-Japan) for 1 h at 25°C. After 
washing with saline containing 0.05% Tween 20, the captured HRP 
activities were measured by the method escribed in [13]. The hybrido- 
mas in the selected wells were cloned by limiting dilution method, and 
reactivities of the candidates were confirmed by ELISA again. 
2.6. SDS-PAGE and Western-blotting 
Tricine-SDS-PAGE system [14] was employed for the resolution of 
small proteins uch as BLMA at lower acrylamide (10%) concentra- 
tions than in glycine-SDS-PAGE system [15] which have an insufficient 
resolving power below 10 kDa. The protein was electrophoretically 
transferred to a nitrocellulose membrane and then detected by enzyme- 
antibody method using the specific antibody. 
3. Results and discussion 
3.1. Overexpressions o f BLMA and BLMS in E. coli 
Since we could not obtain BLMA from E. coli harboring 
p 181EB 1 because of the less amount of production, we tried to 
overproduce BLMA as a protein fused to the maltose-binding 
protein (MBP) [11]. The plasmid pMALBI0  was used to pro- 
duce a fusion protein between BLMA and MBP proteins. Since 
the fusion protein (Fig. 2A, lane 2) contains a recognition site 
digested with blood coagulation factor X, protease, it was 
cleavaged into the two domains (Fig. 2A, lane 3). The BLMA 
was purified to homogeneity by affinity chromatrography to a 
closslinked amylose-resin (Fig. 2A, lane 5). Although the open 
reading frame of bhnA consisting of 366 bp, is predicted to 
encode a protein of Mr = 13,179 [2], BLMA always migrated 
on Tricine-SDS-PAGE at about 15.5 kDa, which is larger than 
expected. We confirmed that the first 20 amino acid sequence 
from the N-terminus was Ile-Ser-Glu-Phe-Val-Val-Lys-Phe- 
Leu-Gly-Ala-Val-Pro-Val-Leu-Thr-Ala-Val-Asp-Val and iden- 
tical with that deduced from the nucleotide sequence of blmA 
[2] except the additional Ile-Ser-Glu-Phe sequence at the N- 
terminus (Fig. 1). We also sequenced the N-terminal amino acid 
of BLMA expressed irectly under the control of trp promoter. 
The N-terminal was Met-Val-Lys-Phe-Leu-Gly-Ala-Val-Pro- 
Val-Leu-Thr-Ala-Val-Asp, indicating that the initiator GTG 
codon for blmA is read as Met but not Val, and the N-terminal 
Met is not processed by the N-terminal Met-aminopeptidase in 
E. coli. 
The isoelectric point (pI) of the purified BLMA, which was 
measured with PAGE containing carrier ampholites (pH 3 5, 
Bio-Lyte, Bio-Rad Laboratories, California, USA), was 4.67 
(data not shown). The theoritical pI calculated from the 
(a)  Pr imer A 
EcoRI I b lmA~ 
1-GGGAGAATTCGTGGTGAAATTCTTGGGTGC-30 
start codon 
Pr imer B 
BamHI [ b lmA, 
1-GAGGGGATCCGGGGTCACTCCCCCGCGGTG-3o 
stop codon 
Xmnl EcoRI rb lwA~ 
(b) malE . . . .  CTCGGGATCGAGGGAAGGATTTCAGAATTCGTGGTGAAA . . . .  
1 1 eSerG I uPheVa I Va I Lys 
Fig. l. Design of PCR primers to antisense- (primer A) and sense 
(primer B)-DNAs to amplify the artificial blmA gene (a), and the nucle- 
otide and amino acid sequences of 5'-end of blmA fused to malE having 
the recognition (~)  and cleavage sites (T) for blood coagulation factor 
X, protease between the two domains (b). 
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Fig. 2. Tricine-SDS-PAGE of BLMA purified from £ coli harboring pMALB10 (A) and Western blot analysis ofanti-BLMA monoclonal ntibody 
to B LMA (B). (A) Gel stained with Coomassie brilliant blue. Lanes: 1, standard proteins; 2, MBP/BLMA (1/tg) purified from E. eoli TB 1 harboring 
pMALB10; 3, the sample (4 ,ug) cleavaged between MBP and BLMA with factor X, protease; 4, MBP (1/lg); 5, the purified BLMA (1/lg); 6, Shble 
protein (1 ,ug, purchased from CYRLA, Toulouse, France). Molecular weights are indicated on the left side. (B) Gel stained with Vectastain Elite 
ABC Kit containing the biotinated-anti-mouse IgG (Vector Laboratories, Inc., CA, USA) using anti-BLMA monoclonal ntibody 839-12 for immuno 
blot analysis, lanes: 1 and 3, BLMA (1 ng); 2, Shble protein (100 ng); 4, MBP (100 ng); 5, the sample (50 ng) cleavaged between MBP and BLMA; 
6, MBP/BLMA (10 ng). 
deduced amino acid sequence of BLMA having additional Ile- 
Ser-Glu-Phe at the N-terminus was 4.38, indicating that BLMA 
is an acidic protein similar to the Shble protein which has a very 
low theoritical pI of 3.78 [9]. 
We have previously suggested that BLMA prevents the Bm- 
induced DNA breakage in vitro, and that the prevention is 
likely to occur without enzymatic modification of the drug [2]. 
The present study shows that the antibacterial activity of Bm 
disappeared when incubated with BLMA (data not shown). 
1 2 3 4 5 6 7 
The antibacterial ctivities of pepleomycin and phleomycin was 
also quenched uring incubation with BLMA. However, heat- 
treatment in a boiling water for 10 min or proteinase K-diges- 
tion at 37°C for 60 min of Bm/BLMA complex significantly 
restored the antibacterial activity of the antibiotic (data not 
shown). 
BLMS was directly overproduced under the control of trp 
promoter and practically obtained as a single protein (data not 
shown). We confirmed that the first 15 amino acid sequence 
from the N-terminus was Met-Leu-Gln-Ser-Ile-Pro-Ala-Leu- 
Pro-Val-Gly-Asp-Ile-Lys-Lys and identical with that deduced 
from the nucleotide sequence of blmS. The N-terminal Met of 
Fig. 3. Agarose gel electrophoresis of DNA treated with Bm alone, in 
combinations with BLMS. Bleomycin (Bm) A2 sulfate was used in the 
present study. After BLMS was incubated with Bm (0.5 ¢tM), for 5 min 
at room temperature, 100 mM FeSO4, 1 mM dithiothreitol and the 
linearized-pBR322 plasmid obtained by digestion with EcoRI (0.2/~g), 
were added and kept for 5 rain at room temperature. The reaction 
mixtures were stopped by addition of 40 mM EDTA and subjected to 
agarose gel (0.8%) electrophoresis. Lanes: 1 and 7, DNA; 2-5, 
Bm+ DNA+ BLMS (1.5, 3.0, 4.5 and 6.0 /lM, respectively); 
6, Bm+ DNA. 
Fig. 4. Assay for antibacterial ctivity of Bm by incubation with B L MS. 
Bacillus subtilis IFO3134 was used as a test organism. Bm (5/zg) dis- 
solved in 9 mM Tris-HCl (pH 7.5) was incubated in the absence (1) or 
presence (2) of BLMS (220/tg) in the same buffer for 5 rain at room 
temperature and applied on a paper disk. 
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Fig. 5. The profile of electrophoretic migration of BLMA or BLMS 
incubated with Bm. BLMA (3.75/lg) or BLMS (8.5/lg) was incubated 
with Bm (5 /lg) for 3 h at 16°C and subjected to the native-PAGE 
containing 15% polyacrylamide. Lanes: 1, BLMA without Bm; 
2, BLMA with Bin" 3. BLMS without Bin; 4, BLMS with Bin. 
BLMS is also not processed in E. coli. BLMS prevents the 
Bm-induced DNA breakage in vitro without enzymatic modifi- 
cation of the drug (Fig. 3, lanes 4 and 5). The antibacterial 
activity of Bm disappeared when incubated with BLMS (Fig. 
4). The theoritical molecular weight and pI calculated from the 
deduced amino acid sequence of BLMS were 14, 926 and 4.68, 
respectively. 
We observed that BLMA or BLMS incubated with Bm, 
respectively, migrated more slowly in native-PAGE than those 
without Bm (Fig. 5), indicating that Bm, a cationic antibiotic, 
forms an electrostatic complex by the binding to the acidic 
BLMA or BLMS. 
1 2 3 4 5 6 7 
3.2. Specific binding of anti-BLMA monoclonal antibody to 
BLMA 
For generation of anti-BLMA monoclonal antibodies, we 
used the MBP/BLMA fusion protein to enhance the immuno- 
genecity of BLMA, a low molecular weight protein. Seven 
candidates of anti-BLMA antibodies which showed both anti- 
MBP/BLMA and anti-BLMA activities but not anti-MBP ac- 
tivity were selected by ELISA. In these candidates, an antibody, 
designated 893-12, showed the highest reactivity. Western-blot 
analysis revealed that 893-12 cross reacts with BLMA having 
molecular weight of 14 kDa (Fig. 2B, lane 1 and 3), but not with 
MBP of 43 kDa (Fig. 2B, lane 4), suggesting strongly that 
893-12 is a monoclonal ntibody which recognizes BLMA but 
not MBP. 
When incubated with BLMA, Bm lost the ability to degrade 
DNA (Fig. 6, lane 3). On the other hand, although the Bm- 
induced DNA cleavage was protected when BLMA was pre- 
incubated with the less amounts of 893 12 antibody (Fig. 6, 
lane 4), the ability of Bm to degrade DNA was restored by 
increasing the amounts of the anti-BLMA antibody against 
BLMA (Fig. 6, lanes 5 and 6), suggesting that Bm no longer 
bind to the BLMA which formed the complex with the anti- 
BLMA antibody. 
3.3. Immunological properties of BLMA 
We have previously compared these translated protein se- 
quences from the genes encoding Bm-resistance determinants 
from transposon Tn5, pUBll0, MRSA B-26 [3] and a tal- 
lysomycin-producing microorganism with that from blmA, and 
shown that the homology with the Shble protein from tal- 
lysomycin producer was 60% [2], but were 25-32% with the 
other Bm-resistance d terminants. 
In the present experiments, we analyzed for immunological 
homology between the BLMA and the Shble protein. A poly- 
clonal antibody raised against Shble protein in rabbit did not 
cross react with BLMA (Fig. 7B, lane 2). In addition, Shb/e 
protein did not cross react with the monoclonal ntibody 893- 
12 against BLMA, even when applied at the concentration f 
A 
k]Da 1 2 3 4 
Fig. 6. Agarose gel electrophoresis of DNA treated with Bm alone, in 
combinations with BLMA or anti-BLMA antibody. After BLMA was 
incubated with or without anti-BLMA antibody for 5 min at room 
temperature, Bm (0.5/tM), 100 mM FeSO 4, 1 mM dithiothreitol and 
the linearized-pBR322 plasmid obtained by digestion with EcoRl (0.2 
~tg), were added and kept for 5 min at room temperature. The reaction 
mixtures were stopped by addition of 40 mM EDTA and subjected to
agarose gel (0.8%) electrophoresis. Lanes: 1 and 7, DNA; 2, Bm + 
DNA; 3, Bm + DNA + BLMA (1.15/~g); 445, Bm + DNA + BLMA 
pre-incubated with anti-BLMA antibody (5.78 rug, 11.56/tg and 17.34 
/~g as proteins, respectively). 
97.4 
66.2 
45.0 
31.0 
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14.4 
Fig. 7. Western blot analysis of BLMA and Shble proteins by anti-Shble 
protein antibody. (A) Gel stained with Coomassie brilliant blue. Lanes: 
1, standard proteins; 2and 4, Shb/e protein (1 pg); 3, BLMA (1/lg). 
Molecular weights are indicated on the left side. (B), gel stained with 
Vectastain Elite ABC kit using polyclonal ntibody raised against Shble 
protein in rabbit for imuno blot analysis. Lanes: 1 and 3, Shble protein 
(10 ng); 2, BLMA (10 ng). 
84 M. Sugiyama et al./FEBS Letters 362 (1995) 80~84 
100-fold of BLMA (Fig. 2B, lane 4). In addition, the anti- 
BLMA monoclonal antibody also did not cross react with 
BLMS (data not shown). Thus, these Bm-binding proteins are 
functionally the same between Bm-producing and Bm-resistant 
microorganisms, whereas not immunologically. 
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